Canaccord raised the firm’s price target on Heartflow (HTFL) to $43 from $40 and keeps a Buy rating on the shares. The firm said HeartFlow reported a solid Q4 beat and gave initial 2026 guidance that they believe is highly conservative given the expected momentum its ongoing Plaque Analysis launch should have.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HTFL:
- Closing Bell Movers: Micron down 4% despite above-consensus and record Q2
- Heartflow reports Q4 EPS (29c), consensus (16c)
- Heartflow sees FY26 revenue $218M-$22M, consensus $212.94M
- HeartFlow’s NAVIGATE-PCI Registry: New Data Pathway for AI-Guided Stent Planning and HTFL Investors
- Heartflow announces clinical evidence, landmark registry launch